Roche Holding AG (ROG) expects government austerity measures to boost its medical-diagnostics unit in the next three to five years thanks to broader use of tests to see which patients should use expensive treatments. The number of tests to help single out the patients who will benefit most from Basel, Switzerland-based Roche’s medicines should double within two to three years, Roche Diagnostics Chief Operating Officer Daniel O’Day said in an Aug. 23 interview. “No country is going to be able to afford to increase the percentage of GDP spent on health care,” O’Day said. “What they’re all looking for is how we can take this certain pie we have for health care and better leverage it for society.”
